Figure 6
From: Metformin ameliorates the severity of experimental Alport syndrome
Metformin protects against podocyte dysfunction in Col4a5 G5X Alport syndrome mice. (a) Visualization of indicated podocyte and glomerular cell proteins in renal tissue sections. Scale bars, 50 μm. (b) Quantification of WT1-positive cells in the glomerulus showed losartan or metformin protected against podocyte loss in late stage C57BL/6 Col4a5 G5X vAlport syndrome mice. (c) Quantification of nephrin- and synaptopodin-positive area in the glomerulus showed that the decrease of these podocyte proteins in glomerulus was suppressed in losartan- or metformin-treated C57BL/6 Col4a5 G5X Alport syndrome mice. (d) Quantification of PCNA-positive cells in the glomerulus showed the number of proliferating cells in glomerulus was decreased in losartan- or metformin-treated C57BL/6 Col4a5 G5X Alport syndrome mice. Data are expressed as the means ± S.E. (n = 4 per group). P values were assessed by Dunnett’s test (##P < 0.01 vs WT. *P < 0.05, **P < 0.01 vs vehicle).
